Anne Wojcicki on Genetic Testing, Your Data and The Next Innovation

The transcript discusses 23andMe's transition to a public company, focusing on new opportunities in therapeutics and online healthcare. It addresses challenges in drug development, particularly in collaboration with GSK, and the decline in home DNA kit sales due to privacy concerns. The company emphasizes physician education in genetics and the importance of genetic diversity in databases. It also explores the implications of insurance on data privacy and the challenges of precision medicine due to healthcare incentives.

What new insight or understanding did you gain from this video?